Gamida Cell Ltd (fka GMDAQ)

[midastouch017]

Gamida Cell (GMDA)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Gamida Cell yesterday and set a price target of $20.00. The company’s shares closed last Friday at $4.14.

Gamida Cell has an analyst consensus of Strong Buy, with a price target consensus of $16.25.

https://www.markets.co/analysts-have-conflicting-sentiments-on-these-healthcare-companies-gamida-cell-nasdaq-gmda-pacira-pharmaceuticals-nasdaq-pcrx-and-ptc-therapeutics-nasdaq-ptct/270660/

GAMIDA CELL (GMDA) RECEIVES A BUY FROM OPPENHEIMER

August 11, 2020 Howard Kim Healthcare

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Gamida Cell (GMDA – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $4.15.

Gamida Cell has an analyst consensus of Strong Buy, with a price target consensus of $17.33, a 333.3% upside from current levels. In a report released today, Needham also assigned a Buy rating to the stock with a $17.00 price target.

Based on Gamida Cell’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.6 million. In comparison, last year the company had a GAAP net loss of $15.51 million.

https://www.markets.co/gamida-cell-gmda-receives-a-buy-from-oppenheimer/266997/